The importance of the multidisciplinary team in the decision-making process of patients undergoing neoadjuvant chemotherapy for breast cancer.
Breast cancer
Breast conserving surgery
Mastectomy
Multidisciplinary treatment
Neoadjuvant chemotherapy
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
05 Feb 2024
05 Feb 2024
Historique:
received:
01
11
2023
accepted:
12
01
2024
medline:
5
2
2024
pubmed:
5
2
2024
entrez:
5
2
2024
Statut:
aheadofprint
Résumé
Recent literature suggests that rates of breast conservation surgery (BCS) are lower than expected in patients submitted to neoadjuvant chemotherapy (NAC) for breast cancer. The aim of this study was to underscore the role of the multidisciplinary team (MDT) in the decision-making process of patients who underwent breast surgery after NAC. We conducted a retrospective study on patients with breast cancer treated according to an algorithm developed at the Breast Unit of Northern Sardinia between January 2019 and May 2023. Data collected included demographics, tumor characteristics, upfront treatment (surgery or NAC), type of primary surgery (BCS or mastectomy [Ma]) and patients' adherence to the treatment proposed by the MDT. Overall, 1061 women were treated during the study period, of whom 164 received NAC (Group A) and 897 upfront surgery (Group B). In group A, conversion from BCS ineligibility to BCS eligibility was observed in 47 patients (40.1%). Final surgery in patients who became BCS-eligible after NAC was BCS in 42 cases (89.3%) and Ma in 5 (10.6%). Rates of patients' adherence to the treatment proposed by the MDT were significantly better in the Group A (p = 0.02). Our results suggest that the MDT has a pivotal role in increasing the rates of breast conservation in women submitted to NAC.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Recent literature suggests that rates of breast conservation surgery (BCS) are lower than expected in patients submitted to neoadjuvant chemotherapy (NAC) for breast cancer. The aim of this study was to underscore the role of the multidisciplinary team (MDT) in the decision-making process of patients who underwent breast surgery after NAC.
METHODS
METHODS
We conducted a retrospective study on patients with breast cancer treated according to an algorithm developed at the Breast Unit of Northern Sardinia between January 2019 and May 2023. Data collected included demographics, tumor characteristics, upfront treatment (surgery or NAC), type of primary surgery (BCS or mastectomy [Ma]) and patients' adherence to the treatment proposed by the MDT.
RESULTS
RESULTS
Overall, 1061 women were treated during the study period, of whom 164 received NAC (Group A) and 897 upfront surgery (Group B). In group A, conversion from BCS ineligibility to BCS eligibility was observed in 47 patients (40.1%). Final surgery in patients who became BCS-eligible after NAC was BCS in 42 cases (89.3%) and Ma in 5 (10.6%). Rates of patients' adherence to the treatment proposed by the MDT were significantly better in the Group A (p = 0.02).
CONCLUSIONS
CONCLUSIONS
Our results suggest that the MDT has a pivotal role in increasing the rates of breast conservation in women submitted to NAC.
Identifiants
pubmed: 38315320
doi: 10.1007/s13304-024-01759-w
pii: 10.1007/s13304-024-01759-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Shao J, Rodrigues M, Corter AL, Baxter NN (2019) Multidisciplinary care of breast cancer patients: a scoping review of multidisciplinary styles, processes, and outcomes. Curr Oncol 26:e385–e397. https://doi.org/10.3747/co.26.4713
doi: 10.3747/co.26.4713
pubmed: 31285683
pmcid: 6588064
Biganzoli L, Marotti L, Hart CD et al (2017) Quality indicators in breast cancer care: an update from the EUSOMA working group. Eur J Cancer 86:59–81. https://doi.org/10.1016/j.ejca.2017.08.017
doi: 10.1016/j.ejca.2017.08.017
pubmed: 28963914
Gnant M (2022) Breast surgery after neoadjuvant therapy. Curr Opin Oncol 34:643–646. https://doi.org/10.1097/CCO.0000000000000906
doi: 10.1097/CCO.0000000000000906
pubmed: 36083127
Sang Y, Zhou X, Chi W et al (2022) Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: a single-center retrospective study. Front Oncol 12:984587. https://doi.org/10.3389/fonc.2022.984587
doi: 10.3389/fonc.2022.984587
pubmed: 36387082
pmcid: 9647014
Golshan M, Loibl S, Wong SM et al (2020) Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial. JAMA Surg 155:e195410. https://doi.org/10.1001/jamasurg.2019.5410
doi: 10.1001/jamasurg.2019.5410
pubmed: 31913413
pmcid: 6990971
Bi Z, Qiu PF, Yang T et al (2022) The modified shrinkage classification modes could help to guide breast conserving surgery after neoadjuvant therapy in breast cancer. Front Oncol 12:982011. https://doi.org/10.3389/fonc.2022.982011
doi: 10.3389/fonc.2022.982011
pubmed: 36439466
pmcid: 9690342
Aktas A, Gunay-Gurleyik M, Aker F et al (2023) Does neoadjuvant chemotherapy provide any benefit for surgical de-escalation in luminal B, HER2(-) breast cancers? Cir Cir 91:186–194. https://doi.org/10.24875/CIRU.22000277
doi: 10.24875/CIRU.22000277
pubmed: 37084295
Criscitiello C, Curigliano G, Burstein HJ et al (2016) Breast conservation following neoadjuvant therapy for breast cancer in the modern era: are we losing the opportunity? Eur J Surg Oncol 42:1780–1786. https://doi.org/10.1016/j.ejso.2016.10.011
doi: 10.1016/j.ejso.2016.10.011
pubmed: 27825710
Verdial FC, Mamtani A, Pawloski KR et al (2022) The effect of age on outcomes after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 29:3810–3819. https://doi.org/10.1245/s10434-022-11367-w
doi: 10.1245/s10434-022-11367-w
pubmed: 35246810
Pfob A, Dubsky P (2023) The underused potential of breast conserving therapy after neoadjuvant system treatment - causes and solutions. Breast 67:110–115. https://doi.org/10.1016/j.breast.2023.01.008
doi: 10.1016/j.breast.2023.01.008
pubmed: 36669994
pmcid: 9982288
Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project b-18. J Clin Oncol 15:2483–2493. https://doi.org/10.1200/JCO.1997.15.7.2483 . (PMID: 9215816)
doi: 10.1200/JCO.1997.15.7.2483
pubmed: 9215816
Arlow RL, Paddock LE, Niu X et al (2018) Breast-conservation therapy after neoadjuvant chemotherapy does not compromise 10-year breast cancer-specific mortality. Am J Clin Oncol 41:1246–1251. https://doi.org/10.1097/COC.0000000000000456
doi: 10.1097/COC.0000000000000456
pubmed: 29782362
pmcid: 8077450
Mamtani A, Sevilimedu V, Le T, Morrow M, Barrio AV (2022) Is local recurrence higher among patients who downstage to breast conservation after neoadjuvant chemotherapy? Cancer 128:471–478. https://doi.org/10.1002/cncr.33929
doi: 10.1002/cncr.33929
pubmed: 34597420
Wilson AR, Marotti L, Bianchi S et al (2013) EUSOMA (European society of breast cancer specialists). The requirements of a specialist breast centre. Eur J Cancer 49:3579–3587
doi: 10.1016/j.ejca.2013.07.017
pubmed: 23968730
Fancellu A, Sanna V, Cottu P et al (2018) Mastectomy patterns, but not rates, are changing in the treatment of early breast cancer. Experience of a single European institution on 2315 consecutive patients. Breast 39:1–7. https://doi.org/10.1016/j.breast.2018.02.003
doi: 10.1016/j.breast.2018.02.003
pubmed: 29454174
Fancellu A, Houssami N, Sanna V, Porcu A, Ninniri C, Marinovich ML (2021) Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis. Br J Surg 108:760–768. https://doi.org/10.1093/bjs/znab145
doi: 10.1093/bjs/znab145
pubmed: 34057990
Chang YK, Co M, Kwong A (2020) Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population. Breast Cancer 27:456–463. https://doi.org/10.1007/s12282-019-01037-3
doi: 10.1007/s12282-019-01037-3
pubmed: 31916189
Fancellu A, Porzani S, Prior M et al (2023) Breast-conserving therapy leads to better survival outcomes compared to mastectomy in patients with early breast cancer: evidences from the recent literature. Minerva Surg 78:183–193. https://doi.org/10.23736/S2724-5691.22.09820-3
doi: 10.23736/S2724-5691.22.09820-3
pubmed: 36651505
Gentilini OD, Cardoso MJ, Poortmans P (2017) Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients. Breast 35:32–33. https://doi.org/10.1016/j.breast.2017.06.004
doi: 10.1016/j.breast.2017.06.004
pubmed: 28644995
De la Cruz KuG, Karamchandani M, Chambergo-Michilot D et al (2022) Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol 29:6163–6188. https://doi.org/10.1245/s10434-022-12133-8
doi: 10.1245/s10434-022-12133-8
Zhang X, Li H, Wu F et al (2022) Neoadjuvant chemotherapy combined with breast-conserving surgery in the treatment of triple-negative breast cancer. J Oncol 2022:7847889. https://doi.org/10.1155/2022/7847889
doi: 10.1155/2022/7847889
pubmed: 35664559
pmcid: 9162830
Mukhtar RA, Chau H, Woriax H, ISPY-2 Locoregional Working Group et al (2023) Breast conservation surgery and mastectomy have similar locoregional recurrence following neoadjuvant chemotherapy: results from 1462 patients on the prospective, randomized I-SPY2 trial. Ann Surg. https://doi.org/10.1097/SLA.0000000000005968
doi: 10.1097/SLA.0000000000005968
pubmed: 37325931
Gwark S, Kim HJ, Kim J et al (2023) Survival after breast-conserving surgery compared with that after mastectomy in breast cancer patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 30:2845–2853. https://doi.org/10.1245/s10434-022-12993-0
doi: 10.1245/s10434-022-12993-0
pubmed: 36577865
Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485–1505. https://doi.org/10.1200/JCO.20.03399
doi: 10.1200/JCO.20.03399
pubmed: 33507815
pmcid: 8274745
Catanuto G, Rocco N, Nava MB (2018) Breast conservation following neoadjuvant therapy for breast cancer. Minerva Chir 73:297–299. https://doi.org/10.23736/S0026-4733.18.07727-1
doi: 10.23736/S0026-4733.18.07727-1
pubmed: 29589678
Li Y, Chen H, He J, Fan Z, Zhang H (2023) The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: a multicenter real-world study (CSBrS-012). Front Public Health 11:1100421. https://doi.org/10.3389/fpubh.2023.1100421
doi: 10.3389/fpubh.2023.1100421
pubmed: 36895689
pmcid: 9988895
Spring LM, Fell G, Arfe A et al (2020) Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res 26:2838–2848. https://doi.org/10.1158/1078-0432.CCR-19-3492
doi: 10.1158/1078-0432.CCR-19-3492
pubmed: 32046998
pmcid: 7299787
Magnoni F, Tinterri C, Corso G et al (2023) The multicenter experience in the multidisciplinary Italian breast units: a review and update. Eur J Cancer Prev. https://doi.org/10.1097/CEJ.0000000000000853
doi: 10.1097/CEJ.0000000000000853
pubmed: 37997909